Granted Patent
B2
US 12,220,402 · App. 17/337,077 · Granted Feb 11, 2025
Formulations for personalized methods of treatment
Assignee:
Faeth Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are formulations and methods of administering formulations to starve cells of nutrients, such as amino acids. The formulations can be substantially devoid of one or more non-essential amino acids. A formulation disclosed herein can be given to a subject to treat a disease, for example, cancer. Removing a particular amino acid or a combination of amino acids from the diet of a subject can lead to improved treatment of various diseases, including cancer. Reduction of amino acid levels in a subject reduces the production of proteins, metabolites, lipids, or nucleic acid that can promote cancer growth and metastasis.
Claims (19)
1. A composition for treating a patient with cancer comprising in unit dosage form:
a) a non-essential amino acid comprising glutamate or a salt thereof in an amount from about 4% to about 8% (w/w), wherein the non-essential amino acid or the salt thereof is not part of a polypeptide;
b) a first essential amino acid comprising histidine or a salt thereof in an amount from about 3% to about 7% (w/w) and a second essential amino acid comprising isoleucine or a salt thereof in an amount from about 2% to about 6% (w/w), wherein the first essential amino acid or the salt thereof and the second essential amino acid or the salt thereof are not part of a polypeptide; and
c) a pharmaceutically acceptable excipient,
wherein the composition is devoid of two non-essential amino acids that are serine and salts thereof and glycine and salts thereof.
2. The composition of claim 1 , further comprising a third essential amino acid or a salt thereof, wherein the third essential amino acid or the salt thereof is present in the composition in a different amount from the first essential amino acid or the salt thereof and the second essential amino acid or the salt thereof.
3. The composition of claim 1 , wherein the composition is further devoid of proline and salts thereof.
4. The composition of claim 1 , wherein the composition is further devoid of cysteine and salts thereof.
5. The composition of claim 1 , wherein the unit dosage form has a weight of about 12 grams.
6. The composition of claim 1 , wherein the composition is in a powder form.
7. The composition of claim 1 , wherein the composition further comprises from about 2% to about 5% (w/w) of a K + source.
8. The composition of claim 7 , wherein the K + source comprises potassium citrate, potassium phosphate, potassium chloride, potassium sulfate, potassium gluconate, potassium bicarbonate, potassium aspartate, potassium acetate, potassium orotate, potassium bromate, potassium benzoate, potassium hydroxide, potassium iodide, or a hydrate thereof.
9. The composition of claim 1 , wherein the composition further comprises from about 1% to about 4% (w/w) of a Mg 2+ source.
10. The composition of claim 9 , wherein the Mg 2+ source comprises magnesium citrate, magnesium fumarate, magnesium acetate, magnesium aspartate, magnesium threonate, magnesium glycinate, magnesium chloride, magnesium sulfate, magnesium oxide, magnesium malate, magnesium orotate, magnesium gluconate, magnesium stearate, magnesium carbonate, or a hydrate thereof.
11. The composition of claim 1 , wherein the composition further comprises taurine, a hydrate thereof, or a salt thereof from about 0.05% to about 2% (w/w).
12. The composition of claim 1 , wherein the composition is further devoid of glutamine and salts thereof.
13. The composition of claim 1 , wherein the composition is further devoid of glutamine and salts thereof, and cysteine and salts thereof.
14. The composition of claim 1 , wherein the composition further comprises a flavorant.
15. The composition of claim 1 , wherein the composition further comprises a sweetener.
Assignments (2)
CHANGE OF NAME
Recorded Jun 3, 2026
From: FAETH THERAPEUTICS, INC.
To: FAETH THERAPEUTICS, LLC
Reel/Frame 075821/0655 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 23, 2021
From: MADDOCKS, OLIVER D.K.
To: FAETH THERAPEUTICS, INC.
Reel/Frame 056639/0173 →
Continuity (2)
Provisional Application
63034137
· Jun 3, 2020
References Cited (189)
US 3832465A
· Ghadimi
· 1974
[cited by examiner]
US 4734401A
· Blouin
· 1988
[cited by applicant]
US 4988724A
· Ajani et al.
· 1991
[cited by applicant]
US 6218420B1
· Dioguardi
· 2001
[cited by examiner]
US 6713501B1
· Walser
· 2004
[cited by applicant]
US 20030129262A1
· Epner et al.
· 2003
[cited by applicant]
US 20060280840A1
· Robertson
· 2006
[cited by applicant]
US 20070270355A1
· Garcia et al.
· 2007
[cited by applicant]
US 20070286909A1
· Smith et al.
· 2007
[cited by applicant]
US 20080317886A1
· Sparkman
· 2008
[cited by applicant]
US 20110118528A1
· Longo et al.
· 2011
[cited by applicant]
US 20110153221A1
· Stefanon et al.
· 2011
[cited by applicant]
US 20140087970A1
· Possemato et al.
· 2014
[cited by applicant]
US 20140170259A1
· Poels et al.
· 2014
[cited by applicant]
US 20220193447A1
· Maddocks et al.
· 2022
[cited by applicant]
US 20220400730A1
· Li et al.
· 2022
[cited by applicant]
EP 4190173A1
· 2023
[cited by applicant]
JP 2005289938A
· 2005
[cited by applicant]
JP 2014512803A
· 2014
[cited by applicant]
WO WO9802441A2
· 1998
[cited by applicant]
WO WO0114387A1
· 2001
[cited by applicant]
WO WO2006043090A1
· 2006
[cited by applicant]
WO WO2009077766A1
· 2009
[cited by applicant]
WO WO2010075007A3
· 2010
[cited by applicant]
WO WO2011092469A1
· 2011
[cited by applicant]
WO WO2011143579A2
· 2011
[cited by applicant]
WO WO2012116229A2
· 2012
[cited by applicant]
WO WO2014049566A2
· 2014
[cited by applicant]
WO WO2015075483A1
· 2015
[cited by applicant]
WO WO2016130918A1
· 2016
[cited by applicant]
WO WO2017053328A1
· 2017
[cited by applicant]
WO WO2017144877A1
· 2017
[cited by examiner]
WO WO2018071873A2
· 2018
[cited by applicant]
WO WO2019092455A1
· 2019
[cited by applicant]
WO WO2019118549A1
· 2019
[cited by applicant]
WO WO2019211605A1
· 2019
[cited by examiner]
WO WO2021016132A1
· 2021
[cited by applicant]
WO WO2021247724A1
· 2021
[cited by applicant]
WO WO2021247923A1
· 2021
[cited by applicant]
WO WO2022015951A2
· 2022
[cited by applicant]
WO WO2022132981A1
· 2022
[cited by applicant]
WO WO2023130140A2
· 2023
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2021/035476 on Oct. 12, 2021.
[cited by applicant]
Adams et al., “The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice” Nature (1985) 318:533-538.
[cited by applicant]
Amelio et al., “Serine and glycine metabolism in cancer” Trends Biochem Sci. Apr. 2014; 39(4):191-198.
[cited by applicant]
Anonymous. ClinicalTrials.gov Archive. NCT02337894 on Jan. 13, 2015.Retrived from the Internet: https://clinicaltrails.gov/archive/NCT. Retrieved on Apr. 2, 2017. 5 pages.
[cited by applicant]
Badgley et al., “Absract A41: Leveraging metabolic dependencies in cancer: Cystein addiction in pancreatic cancer cells” Mol Cancer Research (2016) 14(1_Supp): A41, 4 pages.
[cited by applicant]
Barker et al., “Crypt stem cells as the cells-of-origin of intestinal cancer” Nature (2009) 457:608-611.
[cited by applicant]
Bartlett, David L., et al., “Effect of growth hormone and protein intake on tumor growth and host cachexia”, Surgery, 1995, vol. 117, No. 3, pp. 260-267.
[cited by applicant]
Bassiri et al., “Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma” Transl Pediatr. Jul. 2015; 4(3):226-238.
[cited by applicant]
Bertino et al., “Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies” Cancer Biol Ther. Apr. 1, 2011; 11(7):627-632.
[cited by applicant]
Blau et al., eds., “Laboratory Guide to the Methods in Biochemical Genetics” (2008) Berlin Heidelberg, Germany: Springer Verlag. p. 74. 59 pages.
[cited by applicant]
Bunz F et al., “Requirement for p53 and p21 to sustain G2 arrest after DNA damage” Science. Nov. 1998: 282:1497-1501.
[cited by applicant]
CAS Registry No. 1036730-42-3, STN entry date: Jul. 28, 2008, Pidilizumab, 1 page.
[cited by applicant]
CAS Registry No. 1374853-91-4, STN entry date: May 31, 2012, Pembrolizumab, 1 page.
[cited by applicant]
CAS Registry No. 1380723-44-3, STN entry date: Jul. 3, 2012, Atezolizumab, 1 page.
[cited by applicant]
CAS Registry No. 1428935-60-7, STN entry date: Apr. 23, 2013, Durvalumab, 1 page.
[cited by applicant]
CAS Registry No. 1537032-82-8, STN entry date: Feb. 4, 2014, Avelumab, 1 page.
[cited by applicant]
CAS Registry No. 1801342-60-8, STN entry date: Aug. 4, 2015, Cemiplimab, 1 page.
[cited by applicant]
CAS Registry No. 477202-00-9, dated Dec. 19, 2002, 1 page.
[cited by applicant]
CAS Registry No. 70052-12-9, STN entry date: Nov. 16, 1984, Eflornithine, 2 pages.
[cited by applicant]
CAS Registry No. 946414-94-4, STN entry date: Sep. 7, 2007, Nivolumab, 1 page.
[cited by applicant]
CAS Registry No. 96020-91-6, STN entry date: Apr. 21, 1985, Ornithine, 1 page.
[cited by applicant]
Commisso et al., “Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells” Nature (2013) 497:633-637.
[cited by applicant]
Corsetti et al., “Protect and Counter-attack: Nutritional Supplementation with Essential Amino acid Ratios Reduces Doxorubicin-induced Cardiotoxicity in vivo and promote Cancer Cell Death in vitro” J. Cytol. Histol. (20…
[cited by applicant]
Donehower, et al. “Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours”, Nature, Mar. 19, 1992, pp. 215-221, vol. 356.
[cited by applicant]
Dredge, K et al., “The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer” Cancer Chemother Pharmacol. 65, 191-195 (2009).
[cited by applicant]
Erdman et al., “Dietary Reference Intakes For Water, Potassium, Sodium, Chloride, and Sulfate” Institute of Medicine, Feb. 11, 2004, 4 pages.
[cited by applicant]
Extended European Search Report mailed on Sep. 18, 2023, for EP Application No. 23166882.3, 11 pages.
[cited by applicant]
Faubert et al., “Stable isotope tracing to assess tumor metabolism in vivo” Nat Protoc. (2021) Nov. 16(11):5123-5145.
[cited by applicant]
Fiatarone et al., “Exercise training and nutritional supplementation for physical frailty in very elderly people” N. Engl. J. Med. Jun. 23, 1994; 330(25):1769-75.
[cited by applicant]
Fiatarone Singh et al., “The effect of oral nutritional supplements on habitual dietary quality and quantity in frail elders” J. Nutr. Health Aging (2000) 4(1):5-12.
[cited by applicant]
Final Office Action mailed on Aug. 10, 2023, for U.S. Appl. No. 17/338,283, filed Jun. 3, 2021, 14 pages.
[cited by applicant]
Final Office Action mailed on Nov. 24, 2023, for U.S. Appl. No. 18/174,706, filed Feb. 27, 2023, 13 pages.
[cited by applicant]
Final Office Action mailed on Sep. 2, 2022, for U.S. Appl. No. 15/999,666, filed Aug. 20, 2018, 13 pages.
[cited by applicant]
Final Office Action mailed on Sep. 22, 2021, for U.S. Appl. No. 15/999,666, filed Aug. 20, 2018, 11 pages.
[cited by applicant]
Finkelstein et al., “Methionine metabolism in mammals. The methionine-sparing effect of cystine” J Biol Chem. 263(24):11750-11754 (1998).
[cited by applicant]
Geck et al., “Nonessential amino acid metabolism in breast cancer” Advances in Biological Regulation (2016) 62:11-17.
[cited by applicant]
Gravel et al., “Serine deprivation enhances antineoplastic activity of biguanides” Cancer Res. Dec. 15, 2014; 74(24):7521-7533.
[cited by applicant]
Harenza et al., “Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines” Sci Data. Mar. 28, 2017: 4:170033. 8 pages.
[cited by applicant]
Hingorani et al., “Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice” Cancer Cell (2005) 7:469-483.
[cited by applicant]
Hirakawa et al., “Comparative utilization of a crystalline amino acid diet and a methionine-fortified casein diet by young rats and mice” Nutr Res (1984) 4(5):891-895.
[cited by applicant]
Hogarty et al., “ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma” Cancer Res. Dec. 1, 2008; 68(23):9735-9745.
[cited by applicant]
Holbert et al., “Polyamines in cancer: integrating organismal metabolism and antitumour immunity” Nat Rev Cancer.Aug. 2022; 22(8):467-480.
[cited by applicant]
Hui et al., “Glucose feeds the TCA cycle via circulating lactate” Nature. Nov. 2, 2017; 551(7678):115-118.
[cited by applicant]
Hui et al., “Quantitative Fluxomics of Circulating Metabolites” Cell Metab. Oct. 6, 2020; 32(4):676-688. e4.
[cited by applicant]
Institute of Medicine, “Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids” Chapters 6, 7, and 8, Sep. 2002, 323 pages.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/2021/35780 on Oct. 1, 2021. 11 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Apr. 11, 2022, for PCT/US2021/063639, filed on Dec. 15, 2021, 8 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Jun. 26, 2023, for PCT/US2023/60025, filed on Jan. 3, 2023, 9 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/GB2017/050458, mailed Jul. 18, 2017,20 pages.
[cited by applicant]
Kocak et al., “Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma” Cell Death Dis. Apr. 11, 2013; 4(4):e586. 11 pages.
[cited by applicant]
Kshattry S. et al. “Abstract 367: Assessing the therapeutic efficacy of Cyst(e)inase to induce oxidative stress mediated cytotoxicity in pancreatic cancer cells” Experimental and Molecular Therapeutics, 4 pages, 2016.
[cited by applicant]
Labadie et al., “Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis” Clin Cancer Res. Mar. 1, 2019; 25(5):1462-1471.
[cited by applicant]
Labuschagne CF et al., “Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells” Cell Reports 7. 1248-1258, May 22, 2014.
[cited by applicant]
Lancha et al., “Effect of aspartate, asparagine, and carnitine supplementation in the diet on metabolism of skeletal muscle during a moderate exercise” Physiol Behav. Feb. 1995; 57(2):367-71.
[cited by applicant]
Lewis et al., “A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma” Int J Cancer. Dec. 1, 2020; 147(11):3152-3159.
[cited by applicant]
Liberzon et al., “Molecular signatures database (MSigDB) 3.0” Bioinformatics. Jun. 15, 2011; 27(12):1739-1740.
[cited by applicant]
Locasale, “Serine, glycine and one-carbon units: cancer metabolism in full circle” Nat Rev Cancer. Aug. 2013; 13(8):572-583.
[cited by applicant]
Logiudice et al., “Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases” Med Sci (Basel). Feb. 8, 2018; 6(1):12…
[cited by applicant]
Lopez-Lazaro M,Selective amino acid restriction therapy(SAART);a non-pharmacological strategy against all types of cancer cells. Oncoscience 2015;2(10):857-866.
[cited by applicant]
Maddocks et al., “Serine metabolism supports the methionine cycle and DNR/RNA methylation through de novo ATP synthesis in cancer cells” Molecular Cell. (2016) 61:210-221.
[cited by applicant]
Maddocks et al., “Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells” Nature, Dec. 2013; 493(7433): 542-546.
[cited by applicant]
McCormack et al. “Oral nutritional supplement fortified with beta-alanine improves physical working capacity in older adults: a randomized, placebo-controlled study.” Experimental gerontology 48(9) 2013:933-939.
[cited by applicant]
Miyo, M. et al., “Metabolic Adaptation to Nutritional Stress in Human Colorectal Cancer” Scientific Reports (2016) vol. 6, No. 1, 38415, 13 pages.
[cited by applicant]
Morton et al., “Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer” PNAS USA (2010) 107:246-251.
[cited by applicant]
Moser et al., “A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse” Science (1990) 322-324.
[cited by applicant]
NAS. IOM. Food and Nutrition Board, “Dietary Reference Intakes: RDA and AI for Vitamins and Elements” (2017) 3 pages.
[cited by applicant]
Non-Final Office Action mailed on Jan. 5, 2023, for U.S. Appl. No. 17/338,283, filed Jun. 3, 2021, 14 pages.
[cited by applicant]
Non-Final Office Action mailed on Jul. 7, 2023, for U.S. Appl. No. 18/174,706, filed Feb. 27, 2023, 13 pages.
[cited by applicant]
Non-Final Office Action mailed on Mar. 18, 2021, for U.S. Appl. No. 15/999,666, filed Aug. 20, 2018, 8 pages.
[cited by applicant]
Non-Final Office Action mailed on May 10, 2023, for U.S. Appl. No. 15/999,666, filed Aug. 20, 2018, 12 pages.
[cited by applicant]
Notice of Allowance mailed on Jan. 4, 2024, for U.S. Appl. No. 15/999,666, filed Aug. 20, 2018, 12 pages.
[cited by applicant]
Okada, Kenzo, et al., “Tumor glutamine level is negatively correlated with tumor weight in tumor-bearing rats administered a glutamine antagonist and a new imbalanced amino acid solution”, Journal of Clinical Biochemist…
[cited by applicant]
Paddon-Jones et al., “Amino acid ingestion improves muscle protein synthesis in the young and elderly” Am J Physiol Endocrinol Metab. Mar. 2004; 286(3):E321-E328.
[cited by applicant]
Paddon-Jones et al., “Differential stimulation of muscle protein synthesis in elderly humans following isocaloric ingestion of amino acids or whey protein” Experimental Gerontology. Feb. 1, 2006; 41(2):215-219.
[cited by applicant]
Partial European Search Report mailed on Sep. 20, 2023, for EP Application No. EP 23151551.1, 23 pages.
[cited by applicant]
PCT/US2021/035780 International Preliminary Report on Patentability (Chapter I) dated Dec. 6, 2022. 9 Pages.
[cited by applicant]
Polet et al., “Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth” Oncotarget, Jan. 2016; 7(2):1765-1776.
[cited by applicant]
Possemato et al., “Functional genomics reveal that the serine synthesis pathway is essential in breast cancer” Nature Aug. 18, 2011; 476(7360):346-350.
[cited by applicant]
Ran et al., “Genome engineering using the CRISPR-Cas9 system” Nat Protoc. Nov. 2013; 8(11):2281-2308.
[cited by applicant]
Rose WC et al., “Growth on diets devoid of glycine, serine, and cystine, and low in choline” J Biol Chem. (1952) 194:321-328.
[cited by applicant]
Rounbehler et al., “Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma” Cancer Res. Jan. 15, 2009; 69(2):547-553.
[cited by applicant]
Sahu et al., “Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis” Cell Metabolism (2016) 24:753-761.
[cited by applicant]
Search Report, Intellectual Property Office, United Kingdom Application No. GB1609441.9, Mar. 1, 2017,5 pages.
[cited by applicant]
Sholler et al., “A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma” PLoS One. May 27, 2015;10(5):e0127246. 20 pages.
[cited by applicant]
Sholler et al., “Maintenance DFMO Increases Survival in High Risk Neuroblastoma” Sci Rep. Sep. 27, 2018; 8(1):14445. 9 pages.
[cited by applicant]
Snezhkina, A.V. et al., “The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBPβ rather than Enterotoxigenic Bacteroides fragilis Infection” Oxid Med Cell Lon…
[cited by applicant]
Soldin et al., “Pediatric reference ranges” 3rd ed., Washington: AACC Press, (1999) pp. 11-20.
[cited by applicant]
Solerte et al., “Metabolic effects of orally administered amino acid mixture in elderly subjects with poorly controlled type 2 diabetes mellitus” Am J Cardiol. Apr. 22, 2004; 93(8A):23A-29A.
[cited by applicant]
Su et al., “Metabolite Spectral Accuracy on Orbitraps” Anal Chem. Jun. 6, 2017; 89(11):5940-5948.
[cited by applicant]
Su et al., “Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene” Science (1992) 256:668-670.
[cited by applicant]
Tang et al., “Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas” Cancer Res. Apr. 1, 2016; 76(7):1892-1903.
[cited by applicant]
Trumbo et al., “Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids” J Am Diet Assoc. Nov. 2002; 102(11):1621-1630.
[cited by applicant]
Uniprot P01137, Sep. 13, 2023, 14 pages.
[cited by applicant]
Uniprot P14784, Sep. 13, 2023, 7 pages.
[cited by applicant]
Uniprot P16410, Sep. 13, 2023, 11 pages.
[cited by applicant]
Uniprot P25942, Sep. 13, 2023, 8 pages.
[cited by applicant]
Uniprot P43489, Sep. 13, 2023, 6 pages.
[cited by applicant]
Uniprot Q07011, Sep. 13, 2023, 6 pages.
[cited by applicant]
Uniprot Q15116, Sep. 13, 2023, 9 pages.
[cited by applicant]
Uniprot Q495A1, Sep. 13, 2023, 5 pages.
[cited by applicant]
Uniprot Q5ZPR3, Sep. 13, 2023, 9 pages.
[cited by applicant]
Uniprot Q8TDQ0, Sep. 13, 2023, 9 pages.
[cited by applicant]
Uniprot Q9H7M9, Sep. 13, 2023, 7 pages.
[cited by applicant]
Uniprot Q9NZQ7, Sep. 13, 2023, 9 pages.
[cited by applicant]
Uniprot Q9Y6W8, Sep. 13, 2023, 4 pages.
[cited by applicant]
Vigneron AM et al. Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes & Development.2010;24:2430-2439.
[cited by applicant]
Walpole et al., “The weight of nations: an estimation of adult human biomass” BMC Public Health. Jun. 18, 2012; 12:439. 6 pages.
[cited by applicant]
Wang et al., “Peak Annotation and Verification Engine for Untargeted LC-MS Metabolomics” Anal Chem. Feb. 5, 2019; 91(3):1838-1846.
[cited by applicant]
Weiss et al. “Targeted Expression of MYCN Causes Neuroblastoma in Transgenic Mice”, The EMBO Journal (1997), 16(11): 2985-2995.
[cited by applicant]
Wernerman, J., “Clinical use of glutamine supplementation” J Nutr. Oct. 2008; 138(10):2040S-2044S.
[cited by applicant]
Wu et al., “Dietary protein intake and human health” Food Funct. Mar. 2016; 7(3):1251-1265.
[cited by applicant]
Ying et al., “Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism” Cell (2012) 149:656-670.
[cited by applicant]
Zhang et al., “Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery” PLoS One (2013) 8(6):e65880, 10 pages.
[cited by applicant]
Zhang et al., “Polyamine pathway activity promotes cysteine essentiality in cancer cells” Nature Metabolism (2020) 2:1062-1076, 27 pages.
[cited by applicant]
Zhang W. et al., “Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia” Nature Cell Biology, 14(3):276-286 2012.
[cited by applicant]
Extended European Search Report mailed on Feb. 1, 2024, for EP Application No. 23151551.1, 27 pages.
[cited by applicant]
Fu et al., “Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells” Nutr Cancer. (2003) 45(1):60-73.
[cited by applicant]
Ge et al., “Activation of caspases and cleavage of Bid are required for tyrosine and phenylalanine deficiency-induced apoptosis of human A375 melanoma cells” Arch Biochem Biophys. Jul. 1, 2002; 403(1):50-58.
[cited by applicant]
Yan et al., “Effects of complex unbalanced amino acids on tumors in mice bearing liver cancer H22” Chinese Journal of Clinical Oncology (2011) 38(3):134-137.
[cited by applicant]
Bonfili et al., “Essential amino acid mixtures drive cancer cells to apoptosis through proteasome inhibition and autophagy activation” FEBS J. Jun. 2017; 284(11):1726-1737.
[cited by applicant]
Extended European Search Report mailed on Jun. 12, 2024, for EP Application No. 21818131.1,10 pages.
[cited by applicant]
Extended European Search Report mailed on Jun. 3, 2024, for EP Application No. 21816784.9, 10 pages.
[cited by applicant]
Hamad et al., “Amino Acids Diets as Model for Investigating Cancer Induced by Acrylamide Produced during Wrong Food Cooking” SOJ Biochem (2018) 4(1): 1-14.
[cited by applicant]
Tajan et al., “Dietary Approaches to Cancer Therapy” Cancer Cell. Jun. 8, 2020; 37(6):767-785.
[cited by applicant]
Butler et al., “Amino Acid Depletion Therapies: Starving Cancer Cells to Death,” Trends in Endocrinology and Metabolism Jun. 2021; 32(6):367-381.
[cited by applicant]
Casero Jr. et al., “Polyamine metabolism and cancer: treatments, challenges and opportunities,” Nature Reviews Cancer. Nov. 2018; 18(11):681-695.
[cited by applicant]
Cavuoto et al., “A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension” Cancer Treatment Reviews Oct. 2012; 38(6):726-736.
[cited by applicant]
Doxsee et al., “Sulfasalazine-Induced Cystine Starvation: Potential Use for Prostate Cancer Therapy” Prostate Feb. 1, 2007; 67(2):162-171.
[cited by applicant]
Non-Final Office Action mailed on Feb. 23, 2024, for U.S. Appl. No. 17/338,283, filed Jun. 3, 2021, 13 pages.
[cited by applicant]
Notice of Allowance mailed on Apr. 12, 2024, for U.S. Appl. No. 15/999,666, filed Aug. 20, 2018, 11 pages.
[cited by applicant]
Notice of Allowance mailed on May 9, 2024, for U.S. Appl. No. 15/999,666, filed Aug. 20, 2018, 9 pages.
[cited by applicant]
Tajan et al., “Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy” Nat Commun. Jan. 14, 2021; 12(1):366. 16 pages.
[cited by applicant]
Yan et al., “Effects of complex unbalanced amino acids on tumors in mice bearing liver cancer H22” Chinese Journal of Clinical Oncology (2011) 38(3):134-137 (with full English Translation). 8 total pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/174,706 mailed Jul. 18, 2024, 20 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/338,283 mailed Aug. 13, 2024, 6 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/338,283 mailed Jul. 17, 2024, 9 pages.
[cited by applicant]
Cited By (1)